drugset / Trial / NCT05053295

Investigator-initiated Pilot Study to Investigate the Efficacy and Safety of Immuncell-LC in Combination With Nivolumab (Opdivo) in Subjects With Advanced or Recurrent Gastric Cancer

NCT05053295

Unknown 20 enrolled Gangnam Severance Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study was planned to evaluate the efficacy and safety of combination therapy of Immuncell-LC and nivolumab in patients with relapsed or advanced gastric adenocarcinoma or gastro-esophageal junction cancer.

Timeline

Start
2021-07-02
Primary completion
2023-07-01
Completion
2023-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immuncell-LC Cell therapy Intravenous
Subject Nivolumab Monoclonal antibody Intravenous